0QGJ.L - Medigene AG

LSE - LSE Delayed price. Currency in EUR
1.6600
+0.1050 (+6.75%)
At close: 09:04AM BST
Stock chart is not supported by your current browser
Previous close1.5550
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume79
Avg. volume7
Market cap407,647
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)-0.4060
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs

    Medigene is building a broad KRAS library consisting of multiple T cell receptors (TCRs) targeting multiple KRAS mutations and multiple HLAs, covering large patient populations suffering from solid tumors with high unmet needKRAS TCR-T programs to benefit from combination with Medigene’s expanded library of proprietary product enhancement technologies including its PD1-41BB and potentially CD40L-CD28 costimulatory switch receptorsManagement to host an R&D Event to discuss pipeline expansion and

  • Globe Newswire

    Medigene AG to participate at BIO International in Boston

    Planegg/Martinsried, May 30, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA. BIO International Conventionhttps://www.bio.org/events/bio-international-convention Date: June 5-8, 2023, Location: Boston, MA Medigene’s management team will be available for one-on-one meetings

  • Globe Newswire

    Medigene AG Expands Patent Portfolio for its End-to-End Platform

    Planegg/Martinsried, May 22, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor. Medigene's PD1-41BB costimulatory switch receptor technology was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene. “We are delighted

  • Globe Newswire

    Medigene AG to present at upcoming investor conferences

    Planegg/Martinsried, May 8, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following upcoming investor conferences: Bio€quity Europe 2023 https://conferences.biocentury.com/bioequity-europe Date: May 14-16, 2023, Dublin, IrelandPresentation: Monday, May 15, 2:33 – 2:45 pm (local time)Presenter: Dr. Selwyn Ho, CEO German Spring Conference 2023 htt

  • Globe Newswire

    Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment

    Planegg/Martinsried, May 4, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents the webtool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), taking place May 3-5, 2023, in Mainz, Germany. The Expitope webtool originates from a long standing collaboration between Medigene Immunotherapies GmbH and Prof. Dmitrij Fris

  • Globe Newswire

    Medigene AG reports financial results and business update for Q1 2023

    Focus on executing the strategic plan and delivering shareholder valueMDG1015 pre-clinical data underline potential in solid tumor therapy Subsequent to Q1, expansion of tools and technologies in our end-to-end technology platform Guidance confirmed; cash runway maintained through Q4 2024 Martinsried/Munich, May 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, toda

  • Globe Newswire

    Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors

    Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients with solid tumorsCD40L-CD28 costimulatory switch receptor engages the broader immune system by interacting with and activating non-tumor cell types residing in the immunosuppressive tumor microenvironment (TME)CD40L-CD28 costimulatory switch receptor provides the po

  • Globe Newswire

    Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

    Martinsried/Munich, April 27, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy (CIMT) annual meeting being held on May 3-5, 2023, in Mainz. The data to be presented will focus on Expitope 3.0, an in silico tool to identify immunogenic epitopes as suitable T cell receptor (TCR) target specificities. Mo

  • Globe Newswire

    Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers

    MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early response on treatment at week 4, of which one patient experienced disease progression by week 12MDG1011 TCR-T cells detected in peripheral blood within four weeks of treatment, with detection still possible in one patient at twelve months Martinsried/Munich, April 24, 2023. Medigene AG (Medigene, FSE

  • Globe Newswire

    New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)

    Martinsried/Munich, April 18, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents preclinical data on MDG1015, a T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1) combined with the Company’s PD1-41BB switch receptor technology at the AACR Annual Meeting 2023, taking place April 14-19, 2023,

  • Globe Newswire

    Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting

    Martinsried/Munich, April 11, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the European Society for Blood and Marrow Transplantation (EBMT) 2023 annual meeting being held on April 23-26, 2023 in Paris. The data to be presented show the full results from the CD-TCR-001 dose escalation study with MDG1011, a T cell receptor engineered T cell

  • Globe Newswire

    Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development

    Martinsried/Munich, April 04, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston on April 04, 2023. The title of her presentation will be “Case Study Spotlight: Introducing Innovations at Each Step of

  • Globe Newswire

    Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs

    Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, and the National Cancer Institute (NCI) will collaborate to evaluate the potential of Medigene’s proprietary T cell receptors (TCRs) to be used in new cell constructs for the treatment of solid tumors. NCI is part of the National Institutes of Health. “We are very pleased to begi

  • Globe Newswire

    Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update

    Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3 million milestone payment from 2seventy bioStrengthened leadership with key hires in Corporate Development & Strategy, Investor Relations & Corporate Communications and Clinical Research & DevelopmentCash runway maintained through 4Q 2024Company to host a conference call today, March 29, 2023, at 3 pm

  • Globe Newswire

    Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston

    Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 4th TCR-based Therapies for Solid Tumors Summit in Boston from April 3 to 5, 2023. On April 4, 2023, Prof. Schendel will first join the Industry Leaders’ Fireside Chat ”What’s Next for T-Cell Receptor Therapies?”, followed by her presentation (see detai

  • Globe Newswire

    Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development

    Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today the appointment of Kirsty Crame, MD as Vice President, Head of Clinical Research & Development. “We are delighted to welcome Kirsty to Medigene to lead our clinical development activities. Her capabilities in drug development and proven track record of setting st

  • Globe Newswire

    Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting

    Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2023 being held on April 14-19, 2023. The work to be presented shows that T cells carrying a NY-ESO-1-specific T cell receptor (TCR) combined with a chimeric PD1-41BB switch recep

  • Globe Newswire

    Medigene AG to report full year 2022 financial results on March 29, 2023

    Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023. Following the release of the full year 2022 financial results on Medigene’s website, the company will host a conference call that same day at 3

  • Globe Newswire

    Medigene Amends 2022 Financial Guidance

    MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2022. The company maintains its guidance on expected revenues to be approximately €30-32 million in 2022. Research and development costs will increase fro

  • Globe Newswire

    Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells

    MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. Dolores Schendel Medigene, Chief Scientific Officer, has been invited to present at the CAR-TCR Summit in London on February 23, 2023, on the topic “Implementing Automation & Innovation to Improve Manufacturing of TCR-T Cells”.

  • Globe Newswire

    Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

    MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023. Members of Medigene's management team will participate in a fireside chat and will be available for virtual one-on-one meetings with registe

  • Globe Newswire

    Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London

    MARTINSRIED, Germany and MUNICH, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 6th Annual CAR-TCR Summit Europe in London from February 21 to 23, 2023. CAR-TCR Summit Europe www.cartcr-europe.com Date: February 23, 2023Presenter: Prof. Dr. Dolores Schendel, CSOPresentation: Implementing Auto

  • Globe Newswire

    Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications

    MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today the appointment of Pamela Keck as Vice President, Head of Investor Relations and Corporate Communications. “Pamela’s extensive investor relations experience in the biotech industry and wealth of financial expertise will be invaluabl

  • Globe Newswire

    Medigene Receives $3 Million Milestone Payment from 2seventy bio

    Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a

  • Simply Wall St.

    Investors in Medigene (ETR:MDG1) have unfortunately lost 83% over the last five years

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...